Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review

Culp, 2020, Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates, Eur Urol, 77, 38, 10.1016/j.eururo.2019.08.005

Taitt, 2018, Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location, Am J Mens Health, 12, 10.1177/1557988318798279

Fletcher, 2020, Contemporary National Trends in Prostate Cancer Risk Profile at Diagnosis, Prostate Cancer Prostatic Dis, 23, 10.1038/s41391-019-0157-y

Kensler, 2021, Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation, J Natl Cancer Inst, 113, 10.1093/jnci/djaa171

Hamdy, 2016, 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer, N Engl J Med, 375, 10.1056/NEJMoa1606220

Moris, 2020, Benefits and Risks of Primary Treatments for High-Risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review, Eur Urol, 77, 10.1016/j.eururo.2020.01.033

Teo, 2019, Treatment of Advanced Prostate Cancer, Annu Rev Med, 70, 10.1146/annurev-med-051517-011947

Catton, 1997, Palliative Radiotherapy in Prostate Cancer, Semin Urol Oncol, 15, 65

Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial - ScienceDirect

Rao, 2019, Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure, Am Soc Clin Oncol Educ Book, 10.1200/EDBK_239041

Onal, 2021, Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment, Prostate., 81, 10.1002/pros.24132

Foster, 2019, Oligometastatic Prostate Cancer: Reality or Figment of Imagination, Cancer, 125, 10.1002/cncr.31860

Larbi, 2016, (WB-MRI) Assessment of Metastatic Spread in Prostate Cancer: Therapeutic Perspectives on Targeted Management of Oligometastatic Disease, Prostate., 76, 10.1002/pros.23196

Müller, 2022, Oligometastatic Disease in Biochemical Recurrence of Prostate Cancer: Prevalence on PSMA PET/CT and Consecutive Metastasis-Directed Therapy - Experience at a Tertiary Referral Center, Nukl Nucl Med, 10.1055/a-1697-8111

Halsted, 1894, The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital From June, 1889, to January, 1894, Ann Surg, 20, 497, 10.1097/00000658-189407000-00075

Fisher, 1980, Laboratory and Clinical Research in Breast Cancer–a Personal Adventure: The David A. Karnofsky Memorial Lecture, Cancer Res, 40

Hellman, 1994, Karnofsky Memorial Lecture. Natural History of Small Breast Cancers, . J Clin Oncol Off J Am Soc Clin Oncol, 12, 10.1200/JCO.1994.12.10.2229

Deek, 2021, The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited, Eur Urol, 80, 10.1016/j.eururo.2020.12.040

Tomlinson, 2007, Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure, J Clin Oncol, 25, 10.1200/JCO.2007.11.0833

Gomez, 2019, Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study, J Clin Oncol, 37, 10.1200/JCO.19.00201

Wang, 2022, Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC, J Natl Cancer Inst, djac015, 10.1093/jnci/djac015

Trovo, 2018, Radical Radiation Therapy for Oligometastatic Breast Cancer: Results of a Prospective Phase II Trial, Radiother Oncol J Eur Soc Ther Radiol Oncol, 126, 10.1016/j.radonc.2017.08.032

Milano, 2019, Oligometastatic Breast Cancer Treated With Hypofractionated Stereotactic Radiotherapy: Some Patients Survive Longer Than a Decade, Radiother Oncol J Eur Soc Ther Radiol Oncol, 131, 45, 10.1016/j.radonc.2018.11.022

Franzese, 2020, Liver Metastases-Directed Therapy in the Management of Oligometastatic Breast Cancer, Clin Breast Cancer., 20, 10.1016/j.clbc.2020.05.006

Prostate Cancer

Hofman, 2020, Prostate-Specific Membrane Antigen PET-CT in Patients With High-Risk Prostate Cancer Before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study, Lancet Lond Engl, 395, 10.1016/S0140-6736(20)30314-7

Tsai, 2021, Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast, Int J Radiat Oncol, 111, 10.1016/j.ijrobp.2021.09.014

Ali, 2021, Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial, JAMA Oncol, 7, 10.1001/jamaoncol.2020.7857

Kyriakopoulos, 2018, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial, J Clin Oncol Off J Am Soc Clin Oncol, 36, 10.1200/JCO.2017.75.3657

Lester-Coll, 2021, Cost-Effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2020.33787

Boevé, 2019, Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined With Concurrent Radiation Therapy to the Prostate in Patients With Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data From the HORRAD Trial, Eur Urol, 75, 10.1016/j.eururo.2018.09.008

Burdett, 2019, Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-Analysis, Eur Urol, 76, 10.1016/j.eururo.2019.02.003

S1802 SWOG

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer2021

Reverberi, 2020, Local and Metastatic Curative Radiotherapy in Patients With De Novo Oligometastatic Prostate Cancer, Sci Rep, 10, 17471, 10.1038/s41598-020-74562-3

Deantoni, 2020, Prostate Cancer With Low Burden Skeletal Disease at Diagnosis: Outcome of Concomitant Radiotherapy on Primary Tumor and Metastases, Br J Radiol, 93, 20190353, 10.1259/bjr.20190353

Reyes, 2020, Multidisciplinary Total Eradication Therapy (TET) in Men With Newly Diagnosed Oligometastatic Prostate Cancer, Med Oncol Northwood Lond Engl, 37, 60, 10.1007/s12032-020-01385-7

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer2022

Preisser, 2021, Management and Treatment Options for Patients With De Novo and Recurrent Hormone-Sensitive Oligometastatic Prostate Cancer, Prostate Int, 9, 10.1016/j.prnil.2020.12.003

A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]2022

Palma, 2020, Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial, J Clin Oncol Off J Am Soc Clin Oncol, 38, 10.1200/JCO.20.00818

Sogono, 2019, SABR-COMET: A New Paradigm of Care Lights Up the Twilight of Metastatic Disease, Ann Transl Med, 7, 10.21037/atm.2019.10.96

Ost, 2018, Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial, J Clin Oncol, 36, 10.1200/JCO.2017.75.4853

Phillips, 2020, Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial, JAMA Oncol, 6, 10.1001/jamaoncol.2020.0147

Glicksman, 2021, Curative-Intent Metastasis-Directed Therapies for Molecularly-Defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis, Eur Urol, 80, 10.1016/j.eururo.2021.02.031

Kneebone, 2018, Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-Specific Membrane Antigen Positron Emission Tomography, Eur Urol Oncol, 1, 10.1016/j.euo.2018.04.017

Siva, 2018, Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial, Eur Urol, 74, 10.1016/j.eururo.2018.06.004

De Bleser, 2020, A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer, Cancers, 12, E132, 10.3390/cancers12010132

Qu, 2021, Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial, Int J Radiat Oncol Biol Phys, 109, 10.1016/j.ijrobp.2020.12.001

PhaseAII Double-Blinded Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy With or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Ghent. Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: A Randomized Phase II Trial (DART)2021

Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology2021

Cancer Research GroupECOG-ACRIN Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Pezzulla, 2021, Stereotactic Body Radiotherapy to Lymph Nodes in Oligoprogressive Castration-Resistant Prostate Cancer Patients: A Post Hoc Analysis From Two Phase I Clinical Trials, Clin Exp Metastasis, 38, 10.1007/s10585-021-10126-7

Onal, 2021, Stereotactic Radiotherapy to Oligoprogressive Lesions Detected With 68Ga-PSMA-PET/CT in Castration-Resistant Prostate Cancer Patients, Eur J Nucl Med Mol Imaging, 48, 10.1007/s00259-021-05298-z

Deek, 2021, Metastasis-Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer, Eur Urol Oncol, 4, 10.1016/j.euo.2020.05.004

Franzese, 2022, Oligoprogressive Castration-Resistant Prostate Cancer Treated With Metastases-Directed Stereotactic Body Radiation Therapy: Predictive Factors for Patients’ Selection, Clin Exp Metastasis, 39, 10.1007/s10585-022-10158-7

Berghen, 2021, Progression-Directed Therapy for Oligoprogression in Castration-Refractory Prostate Cancer, Eur Urol Oncol, 4, 10.1016/j.euo.2019.08.012

Triggiani, 2019, Metastasis-Directed Stereotactic Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer: A Multicenter Study, World J Urol, 37, 10.1007/s00345-019-02717-7

Triggiani, 2017, Efficacy of Stereotactic Body Radiotherapy in Oligorecurrent and in Oligoprogressive Prostate Cancer: New Evidence From a Multicentric Study, Br J Cancer., 116, 10.1038/bjc.2017.103

FOcal Radiation for Oligometastatic Castration-Resistant Prostate Cancer (FORCE): A Phase II Randomized Trial2021